Ruthigen Inc (NASDAQ:RTGN) in the last week of August announced that it had received approval for Phase I/II Study. It can begin enrollment of patients in its trial meant to test its anti-infection drug RUT58-60. It has already completed a 21-day skin irritation study conducted on 36 human participants, and now will start with double-blind, multi-centered and randomized trial. The enrollment for patients will start … Continue reading Why Making Dramatic Moves : Ruthigen, Inc. (NASDAQ:RTGN), Rite Aid Corporation (NYSE:RAD), ION Geophysical Corporation (NYSE:IO), Guidance Software, Inc. (NASDAQ:GUID), Graham (NYSE:GHM)